GlassScriptPhysician profile
Julian Santos
NPI 1467283499
$1,264.25
in general payments reported to CMS, 2019-2025
19 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $226.69 | 2025 | Rystiggo, Nayzilam, Fintepla |
| Livanova USA, INC. | $172.51 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $168.62 | 2025 | Xcopri |
| Neurelis, INC. | $138.72 | 2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $96.06 | 2025 | Austedo Xr, Ajovy |
| Servier Pharmaceuticals LLC | $58.65 | 2025 | |
| Lundbeck LLC | $52.37 | 2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $51.27 | 2025 | |
| Tonix Medicines, INC. | $47.67 | 2025 | Zembrace Symtouch |
| Neurocrine Biosciences, INC. | $37.19 | 2025 | |
| Biogen, INC. | $36.84 | 2025 | Spinraza, Qalsody |
| Novocure INC. | $36.81 | 2025 | Optune Gio |
| Argenx US, INC. | $34.87 | 2025 | Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $33.64 | 2025 | Crexont |
| W. L. Gore & Associates, INC. | $15.19 | 2025 | Gore Cardioform Septal Occluder |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $14.80 | 2025 | |
| Merz Pharmaceuticals, LLC | $14.40 | 2025 | Xeomin, Inbrija |
| Astrazeneca Pharmaceuticals LP | $14.13 | 2025 | |
| Abbvie INC. | $13.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.